Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-02-2019 | Esophageal Cancer | Review – Cancer Research

Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy

Authors: Yujie Zhang, Yuxin Zhang, Li Zhang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2019

Abstract

Purpose

Esophageal cancer is a common disease in China with low survival rate due to no obvious early symptoms and lack of effective screening strategies. Traditional treatments usually do not produce desirable results in patients with advanced esophageal cancer, so immunotherapy which relies on tumor-related antigens is needed to combat low survival rates effectively. Cancer–testis antigens (CTA), a large family of tumor-related antigens, have a strong in vivo immunogenicity and tumor-restricted expressing patterns in normal adult tissues. These two characteristics are ideal features of anticancer immunotherapy targets and, therefore, promoted the development of some studies of CTA-based therapy. To provide ideas for the role of the cancer–testis antigens MAGE-A, NY-ESO-1, LAGE-1, and TTK in esophageal cancer, we summarized their expression, prognostic value, and development in immunotherapy.

Methods

The relevant literature from PubMed is reviewed in this study.

Results

In esophageal cancer, although the relationship between expression of MAGE-A, NY-ESO-1, LAGE-1, and TTK and prognosis value is still in a controversial situation, MAGE-A, NY-ESO-1, LAGE-1, and TTK are highly expressed and can induce specific CTL cells to produce particular killing effect on tumor cells, and some clinical trials have demonstrated that immunotherapy for esophageal cancer patients is effective and safe, which provides a new therapeutic strategy for the treatment of esophageal cancer in the future.

Conclusion

In this review, we summarize expression and prognostic value of MAGE-A, NY-ESO-1, LAGE-1, and TTK in esophageal cancer and point out recent advances in immunotherapy about them.

Akcakanat A, Kanda T et al (2004) NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 54(1):95–100CrossRefPubMed

Akcakanat A, Kanda T et al (2006) Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: implications for immunotherapy. Int J Cancer 118(1):123–128CrossRefPubMed

Aung PP, Liu YC et al (2014) Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol 45(2):259–267CrossRefPubMed

Ayyoub M, Memeo L et al (2014) Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS. Cancer Immunol Res 2(10):943–948CrossRefPubMed

Bolli M, Schultz-Thater E et al (2005) NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer 115(6):960–966CrossRefPubMed

Bonehill A, An MTVN et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15(10):3366–3375CrossRefPubMed

Bujas T, Marusic Z et al (2011) MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma. Eur J Histochem 55(1):e7CrossRefPubMedPubMedCentral

Chapman CJ, Thorpe AJ et al (2011) Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 17(6):1474–1480CrossRefPubMed

Chen YT, Panarelli NC et al (2014) Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions. Cancer Immunol Res 2(5):480–486CrossRefPubMed

Chen WQ, Zuo TT et al (2017) Cancer incidence and mortality in China in 2013. Cancer Lett 39(10):795

Chen X, Yu C et al (2018) A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer. Theranostics 8(9):2348–2360CrossRefPubMedPubMedCentral

Choi M, Min YH et al (2017) TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability. Br J Pharmacol 174(12):1810–1825CrossRefPubMedPubMedCentral

Cuffel C, Rivals JP et al (2011) Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 128(11):2625–2634CrossRefPubMed

Duperret EK, Liu S et al (2018) A designer cross-reactive DNA immunotherapeutic vaccine that targets multiple MAGE-A family members simultaneously for cancer therapy. Clin Cancer Res 24(23):6015–6027CrossRefPubMedPubMedCentral

Dyrskj TL, Zieger K et al (2012) Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. 107(1):116–122

Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349(23):2241–2252CrossRefPubMed

Forghanifard MM, Gholamin M et al (2011) Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy. Cancer Biol Ther 12(3):191–197CrossRefPubMed

Forghanifard MM, Gholamin M et al (2014) Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development. Med Oncol 31(10):191CrossRefPubMed

Fossa A, Alsoe L et al (2004) Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 53(5):431–438CrossRefPubMed

Fratta E, Coral S et al (2011) The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 5(2):164–182CrossRefPubMedPubMedCentral

Fujita S, Wada H et al (2004) NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 10(19):6551–6558CrossRefPubMed

Gordeeva O (2018) Cancer-testis antigens: unique cancer stem cell biomarkers and targets for cancer therapy. Semin Cancer Biol 53:75–89CrossRefPubMed

Grob J, Mortier L et al (2017) Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open 2(5):e000203CrossRefPubMedPubMedCentral

Grunwald C, Koslowski M et al (2006) Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. Int J Cancer 118(10):2522–2528CrossRefPubMed

Gure AO, Chua R et al (2005) Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11(22):8055–8062CrossRefPubMed

Haier J, Owzcareck M et al (2006) Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res 26(3B):2281–2287PubMed

Hayes SJ, Hng KN et al (2014) Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens. World J Gastroenterol 20(14):4011–4016CrossRefPubMedPubMedCentral

He W, Chen L et al (2018) Gene set enrichment analysis and meta-analysis to identify six key genes regulating and controlling the prognosis of esophageal squamous cell carcinoma. J Thorac Dis 10(10):5714–5726CrossRefPubMedPubMedCentral

Hudolin T, Juretic A et al (2006) Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 66(1):13–18CrossRefPubMed

Iinuma H, Fukushima R et al (2014) Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med 12:84CrossRefPubMedPubMedCentral

Iwahashi M, Katsuda M et al (2010) Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 101(12):2510–2517CrossRefPubMed

James SR, Link PA et al (2006) Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 25(52):6975–6985CrossRefPubMed

Jungbluth AA, Chen YT et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92(6):856–860CrossRefPubMed

Kageyama S, Wada H et al (2013) Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med 11(1):246CrossRefPubMedPubMedCentral

Kageyama S, Ikeda H et al (2015) Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 21(10):2268–2277CrossRefPubMed

Kaistha BP, Honstein T et al (2014) Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells. Br J Cancer 111(9):1780–1787CrossRefPubMedPubMedCentral

Kakimi K, Isobe M et al (2011) A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. 129(12):2836–2846

Kan T, Yamasaki S et al (2006) A new specific gene expression in squamous cell carcinoma of the esophagus detected using representational difference analysis and cDNA microarray. Oncology 70(1):25–33CrossRefPubMed

Kerkar SP, Wang Z et al (2016) MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases. J Immunother (Hagerstown Md 1997) 39(4):181–187

Kim R, Kulkarni P et al (2013) Derepression of cancer/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation. BMC Cancer 13:144CrossRefPubMedPubMedCentral

King JL, Zhang B et al (2018) TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer. Oncogenesis 7(9):69CrossRefPubMedPubMedCentral

Kono K, Mizukami Y et al (2009) Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 100(8):1502–1509CrossRefPubMed

Kono K, Iinuma H et al (2012) Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 10:141CrossRefPubMedPubMedCentral

Kranz LM, Diken M et al (2016) Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534(7607):396–401CrossRefPubMed

Kruit WHJ, Suciu S et al (2013) Selection of Immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma. J Clin Oncol 31(19):2413–2420CrossRefPubMed

Kudela P, Sun Z et al (2011) Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol (Baltim Md 1950) 186(1):312–322CrossRef

Lethe B, Lucas S et al (1998) LAGE-1, a new gene with tumor specificity. Int J Cancer 76(6):903–908CrossRefPubMed

Liang Z, Sun ZY et al (2005) The expression of 11 cancer/testis (CT) antigen genes in esophageal carcinoma. Zhonghua Zhong Liu Za Zhi 27(9):534–537PubMed

Linnekamp JF, Butter R et al (2017) Clinical and biological effects of demethylating agents on solid tumours—a systematic review. Cancer Treat Rev 54:10–23CrossRefPubMed

Lu Y, Parker LL et al (2017) Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J Clin Oncol 35(29):3322–3329CrossRefPubMedPubMedCentral

Maia ARR, De Man J et al (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Ann Oncol 26(10):2180–2192CrossRefPubMed

Mashino K, Sadanaga N et al (2001) Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85(5):713–720CrossRefPubMedPubMedCentral

Mason JM, Wei X et al (2017) Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci USA 114(12):3127–3132CrossRefPubMedPubMedCentral

McCormack E, Adams KJ et al (2013) Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 62(4):773–785CrossRefPubMed

Meek DW, Marcar L (2012) MAGE-A antigens as targets in tumour therapy. Cancer Lett 324(2):126–132CrossRefPubMed

Mengus C, Schultz-Thater E et al (2013) MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. Int J Cancer 132(10):2459–2463CrossRefPubMed

Miao R, Wu Y et al (2016) Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer. Sci Rep 6:33121CrossRefPubMedPubMedCentral

Mills GB, Schmandt R et al (1992) Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem 267(22):16000PubMed

Mizukami Y, Kono K et al (2008) Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 99(7):1448–1454CrossRefPubMed

Morgan RA, Chinnasamy N et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (Hagerstown Md 1997) 36(2):133–151

Odunsi K, Jungbluth AA et al (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63(18):6076–6083PubMed

Oshima Y, Shimada H et al (2016) NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol 51(1):30–34CrossRefPubMed

Piura B, Piura E (2009) Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol 2009:581939CrossRefPubMed

Prasad ML, Jungbluth AA et al (2004) Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck 26(12):1053–1057CrossRefPubMed

Pujol J, Vansteenkiste JF et al (2015) Safety and Immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell lung cancer. J Thorac Oncol 10(10):1458–1467CrossRefPubMed

Rao M, Chinnasamy N et al (2011) Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 71(12):4192–4204CrossRefPubMedPubMedCentral

Rapoport AP, Aqui NA et al (2014) Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 20(5):1355–1365CrossRefPubMedPubMedCentral

Rapoport AP, Stadtmauer EA et al (2015) NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. 21(8):914–921

Riggs JR, Nagy M et al (2017) The discovery of a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor for the treatment of triple negative breast cancer initiated from a phenotypic screen. J Med Chem 60(21):8989–9002CrossRefPubMed

Sang M, Gu L et al (2016) Prognostic significance of MAGE-A11 in esophageal squamous cell carcinoma and identification of related genes based on DNA microarray. Arch Med Res 47(3):151–161CrossRefPubMed

Schooten E, Di Maggio A et al (2018) MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat Rev 67:54–62CrossRefPubMed

Schultz-Thater E, Piscuoglio S et al (2011) MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int J Cancer 129(5):1137–1148CrossRefPubMed

Shan Q, Lou X et al (2013) A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett 328(1):160–167CrossRefPubMed

Sharma P, Shen Y et al (2006) Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442–5447CrossRefPubMed

Shirakura Y, Mizuno Y et al (2012) T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/gammacnull mice. Cancer Sci 103(1):17–25CrossRefPubMed

Suda T, Tsunoda T et al (2007) Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 98(11):1803–1808CrossRefPubMed

Suntharalingam MM (2006) Definitive chemoradiation in the management of locally. Adv Esophageal Cancer 17(1):22–28

Szymiczek A, Carbone M et al (2017) Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. Oncogene 36(46):6501–6507CrossRefPubMedPubMedCentral

Takahashi N, Ohkuri T et al (2012) First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 103(1):150–153CrossRefPubMed

Tanaka T, Nakamura J et al (2017) Promising immunotherapies for esophageal cancer. Expert Opin Biol Ther 17(6):723–733CrossRefPubMed

Tannous BA, Kerami M et al (2013) Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst 105(17):1322–1331CrossRefPubMedPubMedCentral

Tao Y, Chai D et al (2012) Identification of distinct gene expression profiles between esophageal squamous cell carcinoma and adjacent normal epithelial tissues. Tohoku J Exp Med 226(4):301–311CrossRefPubMed

Thomas R, Al-Khadairi G et al (2018) NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 9:947CrossRefPubMedPubMedCentral

Thu KL, Silvester J et al (2018) Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. Proc Natl Acad Sci USA 115(7):E1570–E1577CrossRefPubMedPubMedCentral

Tyagi P, Mirakhur B (2009) MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10(5):371–374CrossRefPubMed

Uenaka A, Wada H et al (2007) T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 7:9PubMedPubMedCentral

van Baren N, Bonnet MC et al (2005) Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23(35):9008–9021CrossRefPubMed

Vansteenkiste J, Zielinski M et al (2013) Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31(19):2396–2403CrossRefPubMed

Vansteenkiste JFPD, Cho BCM et al (2016) Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17(6):822–835CrossRefPubMed

Vaughan HA, Svobodova S et al (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10(24):8396–8404CrossRefPubMed

Whitehurst AW (2014) Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 54:251–272CrossRefPubMed

Wilgenhof S, Van Nuffel AM et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34(5):448–456CrossRefPubMed

Yamabuki T, Daigo Y et al (2006) Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 28(6):1375PubMed

Zhang XM, Huang Y et al (2010) Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 server. Oncol Lett 1(6):1097–1100CrossRefPubMedPubMedCentral

Zhu D, Xu S et al (2018) Synthetic lethal strategy identifies a potent and selective TTK and CLK1/2 inhibitor for treatment of triple-negative breast cancer with a compromised G1-S checkpoint. Mol Cancer Ther 17(8):1727–1738CrossRefPubMed

Title: Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy
Authors: Yujie Zhang
Yuxin Zhang
Li Zhang
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Keywords: Esophageal Cancer
Esophageal Cancer
Published in: Journal of Cancer Research and Clinical Oncology / Issue 2/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02840-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

The role of EP3-receptor expression in cervical dysplasia

Induced expression of GINS complex is an essential step for reactivation of quiescent stem-like tumor cells within the peri-necrotic niche in human glioblastoma

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Effects of VEGFR1+ hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells

Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials